The role of circulating zonulin levels in patients with chronic kidney disease stages 3 to 5 not on dialysis

Zonulin (Zo) has recently been identified as a marker of intestinal permeability. It has previously been linked to type 2 diabetes mellitus, obesity, and cardiovascular disease; however, its role in chronic kidney disease (CKD) remains unclear. This study aimed to investigate the relationship between Zo and systemic inflammation (SI), endothelial dysfunction (ED), and renal function in CKD patients. One hundred sixty-three participants were enrolled in this study and divided into 2 groups (patient and control) according to the presence of CKD stage 3 to 5 not on dialysis. Circulating Zo levels have been investigated as markers of intestinal permeability. Furthermore, vascular cell adhesion molecule 1 (VCAM-1) and Interleukin-6 (IL-6) have been used as biomarkers for ED and SI assessments, respectively. A total of 104 patients with CKD (mean age: 58.9 ± 1.4) and 59 control subjects (mean age: 59.0 ± 1.1) were included, with similar age (P = .934) and sex (P = .196) between the groups. In the comparison analysis, plasma Zo levels in the CKD group (166.16 ± 53.54) were significantly higher than those in the control group (143.30 ± 60.92) (P < .001). In the correlation analysis, the serum Zo level showed a positive correlation with claudin-3 (R = 0.612, P < .001), IL-6 (R = 0.307, P < .001), and creatinine (R = 0.313, P < .001) and a negative correlation with glomerular filtration rate (GFR) (r = -0.320, P < .001). On the other hand, there was no correlation between circulating Zo and VCAM-1 levels (r = -0.139, P = .081). Additionally, according to linear regression analysis, Zo level was significantly associated with GFR after adjusting for age and systolic blood pressure (β = -0.918, P = .012). High serum Zo levels in patients with CKD reflect increased intestinal permeability and are associated with impaired renal function. Moreover, it was thought that Zo levels could be associated with SI; however, novel clinical studies are needed to elucidate their relationship with ED.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2025-05-23
DOI
https://doi.org/10.1097/md.0000000000042185
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The role of circulating zonulin levels in patients with chronic kidney disease stages 3 to 5 not on dialysis

Süleyman Emre Koçyiğit, Saliha Uysal, Hacer Şen, Ali Kırık et al.
Medicine
Chronic Kidney Disease and Diabetes
article

The role of circulating zonulin levels in patients with chronic kidney disease stages 3 to 5 not on dialysis

Süleyman Emre Koçyiğit, Saliha Uysal, Hacer Şen, Ali Kırık, Ömer Toprak, Özge KAMA BAŞCI, Elif Parlak, İldeniz Bilgiçler, Tugcin Mutlu
article en

Abstract

Zonulin (Zo) has recently been identified as a marker of intestinal permeability. It has previously been linked to type 2 diabetes mellitus, obesity, and cardiovascular disease; however, its role in chronic kidney disease (CKD) remains unclear. This study aimed to investigate the relationship between Zo and systemic inflammation (SI), endothelial dysfunction (ED), and renal function in CKD patients. One hundred sixty-three participants were enrolled in this study and divided into 2 groups (patient and control) according to the presence of CKD stage 3 to 5 not on dialysis. Circulating Zo levels have been investigated as markers of intestinal permeability. Furthermore, vascular cell adhesion molecule 1 (VCAM-1) and Interleukin-6 (IL-6) have been used as biomarkers for ED and SI assessments, respectively. A total of 104 patients with CKD (mean age: 58.9 ± 1.4) and 59 control subjects (mean age: 59.0 ± 1.1) were included, with similar age (P = .934) and sex (P = .196) between the groups. In the comparison analysis, plasma Zo levels in the CKD group (166.16 ± 53.54) were significantly higher than those in the control group (143.30 ± 60.92) (P < .001). In the correlation analysis, the serum Zo level showed a positive correlation with claudin-3 (R = 0.612, P < .001), IL-6 (R = 0.307, P < .001), and creatinine (R = 0.313, P < .001) and a negative correlation with glomerular filtration rate (GFR) (r = -0.320, P < .001). On the other hand, there was no correlation between circulating Zo and VCAM-1 levels (r = -0.139, P = .081). Additionally, according to linear regression analysis, Zo level was significantly associated with GFR after adjusting for age and systolic blood pressure (β = -0.918, P = .012). High serum Zo levels in patients with CKD reflect increased intestinal permeability and are associated with impaired renal function. Moreover, it was thought that Zo levels could be associated with SI; however, novel clinical studies are needed to elucidate their relationship with ED.

MedicineVol. 104(21)
Balıkesir University (TR)
Good health and well-being
Openalex Percentile: Top 86%
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.